Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Enrolling by invitation Not applicable Interventional

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery

NCT07050485
View directory record Official record
Conditions
Colon Cancer, Gastrointestinal Cancer
Interventions
PoZibio, Inert placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

NCT00187889
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Eplerenone, Placebo or sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 14, 2026, 5:01 PM EDT
Not listed Not applicable Interventional

Safety Study of Post Tonsillectomy Ibuprofen Use in Adults

NCT01837810
View directory record Official record
Conditions
Secondary Post Tonsillectomy Hemorrhage, Primary Post Tonsillectomy Hemorrhage
Interventions
Ibuprofen
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Fort Sam Houston, Texas • Lackland Air Force Base, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 14, 2026, 5:01 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

NCT04644185
View directory record Official record
Conditions
Covid19
Interventions
SCTA01, Placebo
Drug · Other
Lead sponsor
Sinocelltech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 14, 2026, 5:01 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

NCT03824808
View directory record Official record
Conditions
Kidney Cancer, Prostate Cancer
Interventions
Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 14, 2026, 5:01 PM EDT
Withdrawn Phase 1Phase 2 Interventional

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

NCT02344810
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

NCT07052721
View directory record Official record
Conditions
Rotator Cuff Tears, Shoulder Injuries, Hallux Valgus, Ankle Arthropathy, Clavicle Fracture
Interventions
Experimental Treatment, Sham Comparator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health

NCT00628030
View directory record Official record
Conditions
Pediatric Obesity
Interventions
NOURISH, Wellness Group
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Dupilumab
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression

NCT02300987
View directory record Official record
Conditions
Teratoma
Interventions
LEE011, LEE011 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Albuquerque, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 14, 2026, 5:01 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis

NCT00931359
View directory record Official record
Conditions
Primary Focal Hyperhidrosis, Axilla
Interventions
DTS-G2 System, DTS System (Sham treatment)
Device
Lead sponsor
Miramar Labs
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Sacramento, California • San Diego, California • Sunnyvale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Oct 14, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 14, 2026, 5:01 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C.difficile vaccine, Saline Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
32,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
142
States / cities
Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07090330
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-001 Induction Dose, Placebo, ORKA-001 Maintenance Dose
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

NCT01765309
View directory record Official record
Conditions
Breast Cancer
Interventions
Bilateral mastectomy with reconstruction
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 2Phase 3 Interventional Results available

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

NCT00163020
View directory record Official record
Conditions
Preterm Birth
Interventions
17-alpha-hydroxyprogesterone caproate injectable, Placebo
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 14, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT04162873
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 14, 2026, 5:01 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

NCT04798274
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Continuous Theta Burst Stimulation
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
11 Years to 25 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

StaphVAX in Cardiovascular Surgery Patients

NCT00211913
View directory record Official record
Conditions
Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 14, 2026, 5:01 PM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 14, 2026, 5:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

NCT00587990
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Lower dose mesenchymal stem cell (MSC) injection, Placebo, Higher dose MSC injection
Biological · Genetic
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 14, 2026, 5:01 PM EDT